cromolyn sodium · Sanofi Aventis Us · NDA 016990, 018596, 018887
Intal
Earliest generic entry, as listed · earliest of 2 marketed strengths
Open now
No marketed reference-listed strength; date taken from all listed strengths.
No unexpired patents or exclusivities are listed for this product.
Listed patents · 0 unexpired
No unexpired patents listed.
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 3
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 016990 · 001 · RLD · discontinued | capsule, inhalation | 20MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | open |
| 018596 · 001 · RLD · discontinued | solution, inhalation | 10MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | open |
| 018887 · 001 · discontinued | aerosol, metered, inhalation | 0.8MG/INH | open |